Cyxone further strengthens the team to reinforce the development projects

Report this content

Cyxone (publ.), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, today announced the recruitment of Sally Abdelmoaty as Project Manager to focus on the next step in the development of Cyxone's drug portfolio. The recruitment will strengthen Cyxone’s capabilities in non-clinical drug development. Sally Abdelmoaty will primarily focus on the T20K project but will contribute with her deep scientific knowledge to all projects.

Sally Abdelmoaty holds a PhD in Pharmacology and Toxicology from Karolinska Institutet, Solna, Sweden and Faculty of Pharmacy, Suez Canal University, Egypt. She has long experience in research on rheumatology and antiinflammation as well as from project management in academia and the pharmaceutical industry. Most recently, Dr. Abdelmoaty was employed by Kancera AB, a Swedish biotech company where she was preclinical project manager driving projects within rheumatoid arthritis and multiple sclerosis. She was also involved in the preparations of a clinical trial in Covid-19 patients. 

Malin Berthold, Cyxone’s COO, commented: “We see that Sally brings deep knowledge in our core therapeutic areas, and her expertise in translational research will be a valuable contributor to bring preclinical projects into clinical phase. Her solid scientific background in rheumatology and multiple sclerosis and her strong skills in driving projects will be a great asset for Cyxone, which is currently in an incredibly exciting development and growth phase.” 

Sally Abdelmoaty joined Cyxone on 1 October 2020.


Cyxone AB (publ)
Tara Heitner, CEO
Tel: +46 (0) 707 81 88 08
Adelgatan 21

211 22 Malmö, Sweden

About Cyxone

Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of immune disorders such as multiple sclerosis (MS), rheumatoid arthritis (RA) and Covid-19. The company’s drug portfolio is based on two technological pillars in the form of orally available molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA and Covid-19 in clinical phase II program. Cyxone’s Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50,



Documents & Links